Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response

Nan Wang, Xin Gao, Hang Ji, Shuai Ma, Jiasheng Wu, Jiawei Dong, Fang Wang, Hongtao Zhao, Zhihui Liu, Xiuwei Yan, Bo Li, Jianyang Du, Jiheng Zhang, Shaoshan HuFrontiers in Molecular Biosciences 2022 · DOI

TL;DR

This study leverages machine learning to identify a novel long non-coding RNA (lncRNA) signature (EMTrLS) associated with epithelial-mesenchymal transition (EMT) in lower-grade gliomas (LGG). This signature not only predicts patient prognosis and tumor microenvironment characteristics but also shows promise in guiding therapeutic decisions for chemotherapy and immunotherapy.

What Problem Does This Paper Address?

Lower-grade gliomas (LGGs) are a significant challenge in neuro-oncology due to their potential for aggressive progression and resistance to treatment. A key biological process contributing to this malignancy is epithelial-mesenchymal transition (EMT), which endows cancer cells with enhanced invasiveness and migratory capabilities, ultimately limiting therapeutic efficacy. While long non-coding RNAs (lncRNAs) are known regulators of EMT, a comprehensive understanding of their role in LGG, particularly in relation to the tumor microenvironment (TME) and treatment response, remains incomplete. This paper aims to bridge this gap by identifying a specific lncRNA signature linked to EMT in LGG that can serve as a prognostic marker and potentially predict treatment outcomes.

Methods

The researchers employed a multi-pronged machine learning and bioinformatics approach. They began by identifying EMT-related lncRNAs using Pearson correlation analysis between a set of known EMT genes and lncRNA expression data from LGG samples. To pinpoint prognostic lncRNAs, they utilized univariate Cox regression, followed by random forest analysis to rank feature importance and Kaplan-Meier (K-M) analysis to identify those with significant survival impacts. Finally, LASSO regression was applied to construct a parsimonious EMT-related lncRNA signature (EMTrLS) composed of three key lncRNAs: CRNDE, LINC00665, and NEAT1.

Beyond signature development, the study involved extensive downstream analyses. Gene expression data was used for functional enrichment analysis (GO and KEGG) to understand the biological pathways associated with different EMTrLS levels. Immune infiltration was assessed using multiple tools (e.g., ESTIMATE, TISIDB, ImmuCellAI), and the tumor immunophenotyping (TIP) algorithm was used to evaluate the anticancer immune process. Predictive modeling for immunotherapy response was performed using the Submap algorithm, and chemotherapy response was predicted using the "PRRophetic" package.

Datasets

The study utilized publicly available datasets:

  • The Cancer Genome Atlas (TCGA): A large cohort of LGG samples used for initial discovery and validation.
  • Chinese Glioma Genome Atlas (CGGA): Two datasets (CGGA1 and CGGA2) were used for independent validation of findings.
  • Genotype-Tissue Expression (GTEx): Used to obtain normal brain tissue samples for comparison.

Key Insights and Ideas

  • EMT is a significant driver of LGG malignancy: The study confirms that EMT is activated in LGG and is associated with poorer overall survival, highlighting its critical role in tumor progression.
  • A three-lncRNA signature (EMTrLS) effectively captures EMT status and prognosis: The identified EMTrLS, composed of CRNDE, LINC00665, and NEAT1, demonstrates strong prognostic value, outperforming individual clinicopathological markers in predicting survival.
  • EMTrLS stratifies LGG into distinct molecular and immunological subgroups: The signature not only reflects EMT activation but also correlates with specific genomic alterations, malignant pathways, and distinct tumor microenvironment compositions.
  • EMTrLS predicts therapeutic response: Crucially, the EMTrLS signature shows promise in predicting patient response to both immune checkpoint blockade (ICB) therapy (specifically anti-PD1) and certain chemotherapeutic agents.

Key Results

  • EMTrLS Construction: A signature comprising CRNDE, LINC00665, and NEAT1 was developed using machine learning.
  • Prognostic Value: Patients with high EMTrLS scores exhibited significantly decreased overall survival (p < 0.001) across all datasets. Multivariate Cox regression confirmed EMTrLS as an independent risk factor.
  • TME Characterization: High EMTrLS scores were associated with the activation of malignancy-related and metabolic pathways (glycolytic, glutamate, and glutamine).
  • Immune Infiltration: EMTrLS-high cohorts showed increased infiltration of both tumor-killing immune cells and immunosuppressive cells (Tregs, macrophages), alongside elevated expression of immune checkpoints, suggesting a complex interplay leading to immune evasion.
  • Therapeutic Prediction: EMTrLS stratification predicted a higher likelihood of response to anti-PD1 therapy and indicated differential sensitivity to chemotherapeutic agents like temozolomide and AKT inhibitors. For instance, high EMTrLS was associated with lower IC50 values for temozolomide, suggesting better sensitivity.

Limitations and Future Work

The authors acknowledge several limitations:

  • Incomplete Characterization of EMT lncRNAs: While three hub lncRNAs were identified, the full spectrum of EMT-related lncRNAs and their functions in LGG remains to be explored.
  • Mechanism Elucidation: The precise molecular mechanisms by which these three lncRNAs influence EMT, tumor immunity, and treatment response require further investigation through in vivo and in vitro experiments.
  • Prospective Validation: The predictive power of the EMTrLS signature for immunotherapy response needs to be validated in prospective clinical trials, particularly in LGG cohorts treated with ICB, as such data was not available for this study.
  • Chemotherapy Response Mechanisms: The underlying mechanisms for the observed correlations between EMTrLS and chemotherapy response require further investigation, and extensive drug response experiments are needed for confirmation.
  • Clinical Integration: The EMTrLS model could be further refined by incorporating additional clinical factors to enhance its predictive accuracy for practical clinical applications.

Future work will focus on addressing these limitations, including in-depth mechanistic studies, prospective validation, and the integration of more clinical variables into the EMTrLS model.

Summary updated

Abstract

Epithelial-mesenchymal transition (EMT) confers high invasive and migratory capacity to cancer cells, which limits the effectiveness of tumor therapy. Long non-coding RNAs (lncRNAs) can regulate the dynamic process of EMT at different levels through various complex regulatory networks. We aimed to comprehensively analyze and screen EMT-related lncRNAs to characterize lower-grade glioma (LGG) tumor biology and provide new ideas for current therapeutic approaches. We retrieved 1065 LGG samples from the Cancer Genome Atlas and Chinese Glioma Genome Atlas by machine learning algorithms, identified three hub lncRNAs including CRNDE, LINC00665, and NEAT1, and established an EMT-related lncRNA signature (EMTrLS). This novel signature had strong prognostic value and potential clinical significance. EMTrLS described LGG genomic alterations and clinical features including gene mutations, tumor mutational burden, World Health Organization (WHO) grade, IDH status, and 1p/19q status. Notably, stratified analysis revealed activation of malignancy-related and metabolic pathways in the EMTrLS-high cohort. Moreover, the population with increased EMTrLS scores had increased cells with immune killing function. However, this antitumor immune function may be suppressed by increased Tregs and macrophages. Meanwhile, the relatively high expression of immune checkpoints explained the immunosuppressive state of patients with high EMTrLS scores. Importantly, we validated this result by quantifying the course of antitumor immunity. In particular, EMTrLS stratification enabled assessment of the responsiveness of LGG to chemotherapeutic drug efficacy and PD1 blockade. In conclusion, our findings complement the foundation of molecular studies of LGG, provide valuable insight into our understanding of EMT-related lncRNAs, and offer new strategies for LGG therapy.
BibTeX
@inproceedings{wang2022machine,
  author = {Nan Wang and Xin Gao and Hang Ji and Shuai Ma and Jiasheng Wu and Jiawei Dong and Fang Wang and Hongtao Zhao and Zhihui Liu and Xiuwei Yan and Bo Li and Jianyang Du and Jiheng Zhang and Shaoshan Hu},
  title = {{Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response}},
  booktitle = {Frontiers in Molecular Biosciences},
  year = {2022},
  doi = {10.3389/fmolb.2022.942966},
}
Figure